Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 77,000 shares of the firm's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total value of $1,054,130.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company's stock, valued at $955,945.32. This represents a 52.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oric Pharmaceuticals Stock Down 3.6%
NASDAQ:ORIC opened at $13.24 on Friday. The business's 50-day moving average price is $11.85 and its 200 day moving average price is $10.73. Oric Pharmaceuticals, Inc. has a 52-week low of $7.23 and a 52-week high of $14.93. The firm has a market cap of $1.37 billion, a P/E ratio of -9.81 and a beta of 1.02.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.02). Sell-side analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current year.
Analyst Upgrades and Downgrades
ORIC has been the subject of several recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Oric Pharmaceuticals in a research note on Friday, July 17th. Citigroup decreased their price target on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday, May 5th. Wall Street Zen raised Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, July 25th. Benchmark reiterated a "buy" rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Finally, Stifel Nicolaus assumed coverage on Oric Pharmaceuticals in a research report on Friday, June 12th. They set a "buy" rating and a $14.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Oric Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $19.45.
Read Our Latest Research Report on ORIC
Institutional Trading of Oric Pharmaceuticals
Institutional investors have recently bought and sold shares of the company. Federation des caisses Desjardins du Quebec raised its holdings in shares of Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company's stock valued at $33,000 after purchasing an additional 2,000 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Oric Pharmaceuticals in the 2nd quarter valued at $46,000. Caitong International Asset Management Co. Ltd boosted its holdings in Oric Pharmaceuticals by 184.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company's stock worth $37,000 after purchasing an additional 2,936 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Oric Pharmaceuticals in the third quarter worth $60,000. Finally, CANADA LIFE ASSURANCE Co acquired a new position in Oric Pharmaceuticals during the third quarter worth $65,000. Institutional investors and hedge funds own 95.05% of the company's stock.
Oric Pharmaceuticals Company Profile
(
Get Free Report)
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.
The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
